PT - JOURNAL ARTICLE AU - Wacker, Andreas AU - Jöud, Anna AU - Bernhardsson, Bo AU - Gerlee, Philip AU - Gustafsson, Fredrik AU - Soltesz, Kristian TI - Estimating the SARS-CoV-2 infected population fraction and the infection-to-fatality ratio: A data-driven case study based on Swedish time series data AID - 10.1101/2021.05.27.21257900 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.27.21257900 4099 - http://medrxiv.org/content/early/2021/05/31/2021.05.27.21257900.short 4100 - http://medrxiv.org/content/early/2021/05/31/2021.05.27.21257900.full AB - Aim To estimate the COVID-19 infection-to-fatality ratio (IFR), infection-to-case ratio (ICR), and infection-to-ICU admission ratio (IIAR) in Sweden; to suggest methods for time series reconstruction and prediction.Methods We optimize a set of simple finite impulse response (FIR) models comprising of a scaling factor and time-delay between officially reported cases, ICU admissions and deaths time series using the least squares method. Combined with randomized PCR study results, we utilize this simple model to estimate the total number of infections in Sweden, and the corresponding IFR.Results The model class provides a good fit between ICU admissions and deaths throughout 2020. Cases fit consistently from July 2020, by when PCR tests had become broadly available. We observe a diminished IFR in late summer as well as a strong decline during 2021, following the launch of a nation-wide vaccination program. The total number of infections during 2020 is estimated to 1.3 million.Conclusions A FIR model with a delta filter function describes the evolution of epidemiological data in Sweden well. The fact that we found IFR, ICR and IIAR constant over large parts of 2020 is in contrast with claims of healthcare adaptation or mutated virus variants importantly affecting these ratios. The model allows us to retrospectively estimate the COVID-19 epidemiological trajectory, and conclude that Sweden was far from herd immunity by the end of 2020.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially funded by the ELLIIT Strategic Research Area.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOnly publicly available data sets have been used. They are referenced in the manuscript.AcronymsFIRFinite impulse response [model]ICRInfection-to-case ratioICUIntensive care unitIFRInfection-to-fatality ratioIIARInfection-to-ICU admission ratioLSLeast-squares [method]PCRPolymerace chain reactionSubscripts and modifiersaInfection-to-ICU admissioncCase (detected infection)dInfection-to-fatality (death)∼Weekly central moving averageVariables and symbolsδDirac’s delta distributionγIIAR/ICRσStandard deviationτTime delay (unit:days)bGain parametereError or residual time seriesNNumber of individualspProbabilitytTime index (unit:days)xNew infection time series (not directly observable)yDaily time series (observation)